Regeneron, EYLEA
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as ...
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results